Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as an injection for subcutaneous and intravenous use. It prevents and treats venous thromboembolism, including deep vein thrombosis and pulmonary embolism, in adult patients at risk.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Innohep (tinzaparin sodium) is used in the anticoagulation pathway to prevent and treat venous thromboembolism.

- Prevention of deep vein thrombosis: reduces the risk of clot formation in surgical or immobilized patients. - Treatment of deep vein thrombosis: facilitates clot resolution and prevents extension. - Prevention of pulmonary embolism: lowers the chance of embolic events in high‑risk individuals. - Treatment of pulmonary embolism: aids in clot dissolution and reduces recurrence.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the administration site. - Bruising or hematoma: localized bleeding under the skin. - Minor bleeding: such as gum or nosebleeds. - Nausea or mild gastrointestinal upset. - Headache: transient and usually mild.

Serious or Rare Side Effects: - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop with paradoxical clot risk. - Major bleeding: gastrointestinal, intracranial, or surgical site hemorrhage. - Spinal or epidural hematoma: especially after neuraxial procedures. - Severe allergic reaction: anaphylaxis or angioedema. - Elevated liver enzymes: indicating hepatic stress.

Innohep requires careful patient assessment and monitoring to minimize bleeding and other risks.

- Renal impairment: assess kidney function and adjust dosing as needed. - History of HIT: avoid use in patients with prior heparin‑induced thrombocytopenia. - Concurrent anticoagulants: increased bleeding risk; evaluate necessity and monitor. - Pregnancy: use only if the potential benefit outweighs the risk to the fetus. - Neuraxial anesthesia or spinal puncture: discontinue before the procedure to reduce hematoma risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - Heparin‑induced thrombocytopenia antibodies: contraindicated if positive. - Thrombolytic agents (e.g., alteplase): synergistic effect on hemorrhage.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase minor bleeding. - Antiplatelet agents (aspirin, clopidogrel): additive effect on bleeding; monitor platelet function. - Selective serotonin reuptake inhibitors (SSRIs): potential for increased gastrointestinal bleeding.